Answers are grounded in this paper and cite their sources.
Hyperglycemia severely impairs implant osseointegration due to a hostile bone microenvironment of glycemic fluctuations and oxidative stress. Although responsive biomaterials can dynamically regulate pathological issues, converting harmful signals into a continuous driving force that promotes bone formation remains challenging. Herein, we present a cascade-responsive poly(aryl ether sulfone ketone) (PPESK) implant designed to actively leverage pathological signals for bone regeneration. PPESK features a chitosan-based surface modified with glucose oxidase (GOD), encapsulating black phosphorus (BP)-based nanoparticles loaded with in situ mineralized IGF-1 (mBI). Underlying this design is a glucose/pH/ROS cascade-responsive mechanism where local glucose triggers the catalytic activity of GOD, leading to acid-induced swelling of chitosan and subsequent exposure of mBI. Subsequently, the intrinsic oxidative responsiveness of BP to reactive oxygen species (ROS) facilitates the controlled release of IGF-1. It not only utilizes pathological signal transduction for targeted drug delivery to enhance the osteogenic differentiation potential of BMSCs but also establishes a self-regulated feedback path. By continuously consuming excess glucose and ROS, the implant improves the adverse local environment while promoting bone regeneration. Consequently, the PPESK implant accelerates bone remodeling in vivo, transforming the hyperglycemic microenvironment into an active driver for diabetic bone regeneration and offers a novel therapeutic strategy for stagnated bone repair.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: